



wherein R is an alkyl, m is an integer of 2 - 4 and n is an integer of 1 - 15, provided that R is an alkyl with a carbon number of 5 - 11 in case where n is 1 - 3, and mixtures thereof.--

(Amend claim 4 as follows:)

Amend
 --4. (amended) The preparation for transmucosal administration according to claim 3 wherein salt of bile acid is [one or more numbers thereof] a member selected from the group consisting of sodium taurocholate, sodium glycocholate, [and] sodium deoxycholate, and mixtures thereof.--

(Amend claim 5 as follows:)

--5. (amended) The preparation for transmucosal administration according to claim 3 wherein salt of fusidic acid is [one or more numbers thereof] a member selected from the group consisting of sodium fusidic acid, [and] tauro-24, 25-dihydrofusidic acid, and a mixture thereof.--

(Amend claim 6 as follows:)

Q1 cont
--6. (amended) The preparation for transmucosal administration according to claim 3 wherein salt of glycyrrhizic acid is [one or more numbers thereof] a member selected from the group consisting of salt of glycyrrhizic acid, [and] disodium 3-succinyloxyglycyrrhizic acid (carbenixolon), and a mixture thereof.--

Amend claim 8 as follows:

--8. (amended) The preparation for transmucosal administration according to claim 3 wherein salt of O-acyl-L-carnitine is [one or more numbers thereof] a member selected from the group consisting of salt of O-octanoyl-L-carnitine, salt of O-lauroyl-L-carnitine, [and] salt of O-palmitoyl-L-carnitine, and mixtures thereof.--

(Amend claim 9 as follows:)

Q2
--9. (amended) The preparation for transmucosal administration according to claim 3 wherein phospholipid is [one or more numbers thereof] a member selected from the group consisting of phosphatidylcholine (lecithin), lisophosphatidylcholine (lysolecithin), [and] lysophosphatidylglycerol, and mixtures thereof.--

(Amend claim 10 as follows:)

--10. (amended) The preparation for transmucosal administration according to claim 3 wherein non-ionic surface active agent is [one or more numbers thereof] a member

selected from the group consisting of polyoxyalkylene higher alcohol ether, polyoxyalkylene alkylphenol, [and] sucrose fatty acid ester, and mixtures thereof.--

(Amend claim 11 as follows:)

A² cont
--11. (amended) The preparation for transmucosal administration according to claim 3 wherein non-ionic surface active agent is [one or more numbers thereof] a member selected from the group consisting of polyoxyalkylene lauryl, [and] polyoxyalkylene (24) cholesteryl ether, and a mixture thereof.--

(Amend claim 12 as follows:)

--12. (amended) The preparation for transmucosal administration according to claim 3 wherein cyclodextrin is [one or more numbers thereof] a member selected from the group consisting of α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, [and] dimethyl- β -cyclodextrin, and mixtures thereof.--

Amend claim 14 as follows:

A³
--14. (amended) The preparation for transmucosal administration according to claim 13 wherein higher fatty acid of C₁₆₋₂₀ is [one or more numbers of] a C₁₈ higher fatty acid selected from the group consisting of oleic acid, linoleic acid, [and] linolenic acid, and mixtures thereof.--

(Amend claim 15 as follows:)

--15. (amended) The preparation for transmucosal administration according to claim 3 wherein 1-alkyl-2-pyrrolidone derivative is [one or more numbers thereof selected from the group consisting of] C₄₋₁₂ alkyl.--

(Amend claim 16 as follows:)

--16. (amended) The preparation for transmucosal administration according to claim 15 wherein alkyl is [one or more numbers thereof] a member selected from the group consisting of butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, [and] dodecyl, and mixtures thereof.--

(Amend claim 17 as follows:)

--17. (amended) The preparation for transmucosal administration according to claim 3 wherein azacycloalkane derivative of the [formul] formula [1] is azacycloalkane derivative in which R is C₁₀ alkyl, m is 3 and n is 2[, i.e. 1-[2-(decylthio) ethyl] azacyclopentane-2-one]..--

Amend claim 19 as follows:

--19. (amended) The preparation for transmucosal administration according to claim 1 wherein the compound having vasodilating activity is [one or more numbers thereof] a member selected from the group consisting of calcium channel blocker of molecular weight 200 - 700, prostaglandin E1, isosorbide dinitrate, [and] nitroglycerin, and mixtures thereof.--

(Amend claim 20 as follows:)

Q4 cont
--20. (amended) The preparation for transmucosal administration according to claim 19 wherein calcium channel blocker is a member selected from the group consisting of diltiazem hydrochloride, verapamil hydrochloride, bepridil hydrochloride, nifedipine hydrochloride, nicardipine hydrochloride, [and] fasudil hydrochloride, and mixtures thereof.--

Claim 23, line 7, change "ANP or" to --ANP,--;
line 8, change "thereof." to --thereof,
and mixtures thereof.--.

Amend claim 24 as follows:

Q5
--24. (amended) The preparation for transmucosal administration according to claim 23 wherein calcitonin is a compound selected from the group consisting of eel calcitonin, salmon calcitonin, porcine calcitonin, human calcitonin, [and] chicken [calcitonin] calcitonin, and mixtures thereof.--

Amend claim 26 as follows:

Q6
--26. (amended) The preparation for transmucosal administration according to claim 23 wherein insulin is a compound selected from the group consisting of human insulin, porcine insulin, [and] bovine insulin, and mixtures thereof.--

Claim 27, line 3, change "at least one of the" to
--a--.